Star Combo Pharma Limited reported earnings results for the half year ended December 31, 2022. For the half year, the company reported sales was AUD 11.57 million compared to AUD 11.77 million a year ago. Net loss was AUD 4.36 million compared to AUD 0.000997 million a year ago.

Basic loss per share from continuing operations was AUD 0.00032 compared to AUD 0.00001 a year ago. Diluted loss per share from continuing operations was AUD 0.00032 compared to AUD 0.00001 a year ago.